Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer
- Authors:
- Christina Lönnroth
- Marianne Andersson
- Annika G. Asting
- Svante Nordgren
- Kent Lundholm
-
Affiliations: Department of Surgery, Surgical Metabolic Research Laboratory at Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, University of Gothenburg, SE 413 45 Gothenburg, Sweden - Published online on: September 30, 2014 https://doi.org/10.3892/ijo.2014.2686
- Pages: 2208-2220
-
Copyright: © Lönnroth et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
Flossmann E and Rothwell PM: British Doctors Aspirin Trial and the UK-TIA Aspirin Trial: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 369:1603–1613. 2007. View Article : Google Scholar : PubMed/NCBI | |
Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H and Dunlop MG: Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 59:1670–1679. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, et al: Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 106:1564–1570. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chan AT, Ogino S and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 302:649–658. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, et al: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54:5602–5606. 1994.PubMed/NCBI | |
Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van Wezel T, Fodde R, Kuppen PJ, et al: Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 174:732–739. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K and Lundholm K: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 8:52008. | |
Lönnroth C, Andersson M, Nordgren S and Lundholm K: Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol. 41:15–23. 2012.PubMed/NCBI | |
Blanco Calvo M, Bolós Fernández V, Medina Villaamil V, Aparicio Gallego G, Díaz Prado S and Grande Pulido E: Biology of BMP signalling and cancer. Clin Transl Oncol. 11:126–137. 2009.PubMed/NCBI | |
Mizrak D, Brittan M and Alison M: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rizzino A: Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med. 1:228–236. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hu T, Liu S, Breiter DR, Wang F, Tang Y and Sun S: Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008. View Article : Google Scholar : PubMed/NCBI | |
Friedman JM and Jones PA: MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly. 139:466–472. 2009.PubMed/NCBI | |
Slaby O, Svoboda M, Michalek J and Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI | |
Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lönnroth C and Lundholm K: EP1–4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 121:232–240. 2007. | |
Cahlin C, Lönnroth C, Arvidsson A, Nordgren S and Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 32:909–918. 2008.PubMed/NCBI | |
Chen S, Song X, Chen Z, Li X, Li M, Liu H and Li J: CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 8:e563802013. View Article : Google Scholar : PubMed/NCBI | |
He A, Qi W, Huang Y, Feng T, Chen J, Sun Y, Shen Z and Yao Y: CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. Exp Ther Med. 4:435–441. 2012.PubMed/NCBI | |
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K and Shirouzu K: Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G and Medema JP: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70:719–729. 2010. View Article : Google Scholar : PubMed/NCBI | |
Mak AB, Blakely KM, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T and Moffat J: CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem. 286:41046–41056. 2011. View Article : Google Scholar : PubMed/NCBI | |
Liu A, Yu X and Liu S: Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin J Cancer. 32:483–487. 2013.PubMed/NCBI | |
Wang X and Dai J: Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells. 28:885–893. 2010.PubMed/NCBI | |
Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ and Andrews PW: OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells. 26:3068–3074. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gao Y, Wang X, Han J, Xiao Z, Chen B, Su G and Dai J: The novel OCT4 spliced variant OCT4B1 can generate three protein isoforms by alternative splicing into OCT4B. J Genet Genomics. 37:461–465. 2010. View Article : Google Scholar | |
Gazouli M, Roubelakis MG, Theodoropoulos GE, Papailiou J, Vaiopoulou A, Pappa KI, Nikiteas N and Anagnou NP: OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer. Mol Carcinog. 51:165–173. 2012. View Article : Google Scholar : PubMed/NCBI | |
Fang X, Yu W, Li L, Shao J, Zhao N, Chen Q, Ye Z, Lin SC, Zheng S and Lin B: ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. OMICS. 14:369–384. 2010. View Article : Google Scholar | |
Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM and Suo Z: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 29:1233–1241. 2009.PubMed/NCBI | |
Otsubo T, Akiyama Y, Yanagihara K and Yuasa Y: SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 98:824–831. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wong OG, Huo Z, Siu MK, Zhang H, Jiang L, Wong ES and Cheung AN: Hypermethylation of SOX2 promoter in endometrial carcinogenesis. Obstet Gynecol Int. 2010:6825042010.PubMed/NCBI | |
Cox JL, Wilder PJ, Desler M and Rizzino A: Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One. 7:e440872012. View Article : Google Scholar | |
Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 24:372–376. 2000. View Article : Google Scholar : PubMed/NCBI | |
Boer B, Kopp J, Mallanna S, Desler M, Chakravarthy H, Wilder PJ, Bernadt C and Rizzino A: Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res. 35:1773–1786. 2007. View Article : Google Scholar : PubMed/NCBI | |
Saunders A, Faiola F and Wang J: Concise review: pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells. 31:1227–1236. 2013. View Article : Google Scholar : PubMed/NCBI | |
Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H, Oue N, Yasui W, Clevers H, Schoen RE, et al: Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA. 107:20027–20032. 2010. View Article : Google Scholar : PubMed/NCBI | |
Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K and Mori M: Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol. 15:1530–1537. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Ye L, Xie F, Yang Y, Zhang L and Jiang WG: Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res. 30:1113–1120. 2010.PubMed/NCBI | |
Li W, Cai HX, Ge XM, Li K, Xu WD and Shi WH: Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma. Tumour Biol. 34:669–674. 2013. View Article : Google Scholar : PubMed/NCBI | |
Megumi K, Ishigami S, Uchikado Y, Kita Y, Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono M, et al: Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma. Ann Surg Onco. 19:2066–2071. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M and Ushijima T: Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 97:64–71. 2006.PubMed/NCBI | |
Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D’Incalci M, De Placido S and Pepe S: A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 83:1113–1119. 2012. | |
Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK and Fontana JA: Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 8:e610152013.PubMed/NCBI | |
Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J and O’Driscoll L: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 13:712014. View Article : Google Scholar : PubMed/NCBI | |
John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar | |
Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 256:544–551. 2012. View Article : Google Scholar : PubMed/NCBI | |
Caruso S1, Bazan V, Rolfo C, Insalaco L, Fanale D, Bronte G, Corsini LR, Rizzo S, Cicero G and Russo A: MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis. 1:e322012. View Article : Google Scholar : PubMed/NCBI | |
Chen WS, Leung CM, Pan HW, Hu LY, Li SC, Ho MR and Tsai KW: Silencing of miR-1–1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol Rep. 28:1069–1076. 2012. | |
Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N and Nakagawa M: Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol. 40:1821–1830. 2012.PubMed/NCBI | |
Nohata N, Hanazawa T, Enokida H and Seki N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 3:9–21. 2012.PubMed/NCBI | |
Chen WC, Lin MS, Ye YL, Gao HJ, Song ZY and Shen XY: microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer. Exp Ther Med. 3:1039–1048. 2012.PubMed/NCBI | |
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, et al: Gene map of the extended human MHC. Nat Rev Genet. 5:889–899. 2004. View Article : Google Scholar : PubMed/NCBI | |
Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I and Moffat J: Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep. 2:951–963. 2012.PubMed/NCBI | |
Brandão RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, et al: A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res. 15:R292013. | |
Zhou Y, Cho KJ, Plowman SJ and Hancock JF: Nonsteroidal anti-inflammatory drugs alter the spatiotemporal organization of Ras proteins on the plasma membrane. J Biol Chem. 287:16586–16595. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kim MS, Lee EJ, Kim HR and Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 63:5454–5461. 2003.PubMed/NCBI | |
Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005. View Article : Google Scholar : PubMed/NCBI | |
Alesutan I, Sopjani M, Dërmaku-Sopjani M, Munoz C, Voelkl J and Lang F: Upregulation of Na-coupled glucose transporter SGLT1 by Tau tubulin kinase 2. Cell Physiol Biochem. 30:458–465. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sarkar R, Hunter IA, Rajaganeshan R, Perry SL, Guillou P and Jayne DG: Expression of cyclin D2 is an independent predictor of the development of hepatic metastasis in colorectal cancer. Colorectal Dis. 12:316–323. 2010. View Article : Google Scholar : PubMed/NCBI | |
Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM and Van Ommen B: Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog. 3:82004.PubMed/NCBI | |
Sato T, Oshima T, Yoshihara K, Yamamoto N, Yamada R, Nagano Y, Fujii S, Kunisaki C, Shiozawa M, Akaike M, et al: Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep. 21:211–216. 2009. | |
Lee JH, Kang MJ, Han HY, Lee MG, Jeong SI, Ryu BK, Ha TK, Her NG, Han J, Park SJ, et al: Epigenetic alteration of PRKCDBP in colorectal cancers and its implication in tumor cell resistance to TNFα-induced apoptosis. Clin Cancer Res. 17:7551–7562. 2011.PubMed/NCBI | |
Kim E, Chen F, Wang CC and Harrison LE: CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation. Int J Oncol. 28:191–194. 2006.PubMed/NCBI | |
Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, et al: Cyclin-dependent kinase 5 is amplified and over-expressed in pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res. 17:6140–6150. 2011. View Article : Google Scholar : PubMed/NCBI | |
Blumenthal RD, Leon E, Hansen HJ and Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI | |
Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger U, Herrmann R and Rochlitz C: Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 21:3638–3646. 2003. View Article : Google Scholar : PubMed/NCBI | |
Beauchemin N and Arabzadeh A: Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 32:643–671. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hirakawa M, Takimoto R, Tamura F, Yoshida M, Ono M, Murase K, Sato Y, Osuga T, Sato T, Iyama S, et al: Fucosylated TGF-β receptors transduces a signal for epithelial-mesenchymal transition in colorectal cancer cells. Br J Cancer. 110:156–163. 2014. | |
Zhou F, Mu YD, Liang J, Liu ZX, Chen HS and Zhang JF: Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett. 7:507–512. 2014.PubMed/NCBI | |
Aoi J, Endo M, Kadomatsu T, Miyata K, Ogata A, Horiguchi H, Odagiri H, Masuda T, Fukushima S, Jinnin M, et al: Angiopoietin-like protein 2 accelerates carcinogenesis by activating chronic inflammation and oxidative stress. Mol Cancer Res. 12:239–249. 2014. View Article : Google Scholar | |
Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A and Sgambato A: Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol. 20:923–942. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhao J: Coordination of DNA synthesis and histone gene expression during normal cell cycle progression and after DNA damage. Cell Cycle. 3:695–697. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Chen FQ, Sun YH, Zhou SY, Li TY and Chen R: Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells. J Exp Clin Cancer Res. 30:982011. View Article : Google Scholar : PubMed/NCBI | |
Szyf M: The role of DNA methyltransferase 1 in growth control. Front Biosci. 6:D599–D609. 2001. View Article : Google Scholar : PubMed/NCBI | |
Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A and MacLeod AR: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 33:61–65. 2003. View Article : Google Scholar : PubMed/NCBI | |
Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S and Hirohashi S: DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 27:1160–1168. 2006. View Article : Google Scholar : PubMed/NCBI | |
Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 64:3137–3143. 2004. View Article : Google Scholar : PubMed/NCBI | |
Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T and Yao T: Aberrant p16INK4a methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol. 136:323–331. 2010. | |
Licciardi PV and Karagiannis TC: Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol. 2012:6909012012. View Article : Google Scholar : PubMed/NCBI | |
Ho AS, Turcan S and Chan TA: Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther. 6:223–232. 2013.PubMed/NCBI | |
Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM and Yao TP: The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 68:7561–7569. 2008. View Article : Google Scholar : PubMed/NCBI | |
Fatima N, Yi M, Ajaz S, Stephens RM, Stauffer S, Greenwald P, Munroe DJ and Ali IU: Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. Cancer Epidemiol Biomarkers Prev. 17:3051–3061. 2008. View Article : Google Scholar : PubMed/NCBI | |
van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JM, van Bladeren PJ and van Ommen B: Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 44:143–156. 2005.PubMed/NCBI | |
Li J and Mansmann UR: Modeling of non-steroidal anti-inflammatory drug effect within signaling pathways and mirna-regulation pathways. PLoS One. 8:e724772013. View Article : Google Scholar : PubMed/NCBI | |
Jeck WR, Siebold AP and Sharpless NE: Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell. 11:727–731. 2012. View Article : Google Scholar : PubMed/NCBI | |
Langan RC, Mullinax JE, Raiji MT, Upham T, Summers T, Stojadinovic A and Avital I: Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer. 4:241–250. 2013. View Article : Google Scholar : PubMed/NCBI | |
Tabarestani S and Ghafouri-Fard S: Cancer stem cells and response to therapy. Asian Pac J Cancer Prev. 13:5951–5958. 2012. View Article : Google Scholar : PubMed/NCBI | |
Park JH, McMillan DC, Horgan PG and Roxburgh CS: The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 40:68–77. 2014. View Article : Google Scholar : PubMed/NCBI |